Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial

Font, Albert; Real, Francisco X.; Puente, Javier; Mazon, F.J. Vazquez; Sala, Núria; Virizuela, Juan Antonio; Rodríguez‐Vida, Alejo; Pulido, Enrique Grande; Castellano, Daniel; Climent, Miguel Ángel; Gallardo, E.; Alba, Aránzazu Gonzalez del; Fernández, Pedro; Jares, Pedro; Aldecoa, Ibán; Gibson, Neil; Serra, Josep; Imedio, Esteban Rodrigo; Ehrnrooth, Eva; Mellado, Begoña

doi:10.1093/annonc/mdx371.074

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median PFS was significantly higher in patients with Her-2/ErbB3 alterations (6.6 months vs. 1.4 months; p < 0.001), confirming their response-predicting value. The phase II LUX-Bladder 1 trial [ 30 ] evaluated afatinib in 42 mUC patients with ErbB alterations, divided into two cohorts: 34 patients with Her-2/Her-3 amplification or mutation (cohort A) and 8 patients with EGFR amplification (cohort B). A total of 2 PR and 15 SD were observed among the patients from cohort A (DCR: 50%), with a median PFS of 9.8 weeks and 4 patients (11.8%) free of progression at 6 months.…”

Section: Anti-her-2 Drugs In Uc: Clinical Resultsmentioning

confidence: 99%

Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates

Albarrán

Rosero

Chamorro

et al. 2022

IJMS

View full text Add to dashboard Cite

Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth factor receptor 2 (Her-2) has been identified as a new therapeutic target in medical oncology. However, despite the encouraging results in breast and gastric cancers, clinical trials with anti-Her-2 monoclonal antibodies and tyrosine-kinase inhibitors have shown limited efficacy of this strategy in urothelial tumors. Notably, more favorable data have been recently shown that antibody-drug conjugates are currently emerging as a novel promising approach for Her-2 targeted therapy in advanced urothelial cancer.

show abstract

Section: Anti-her-2 Drugs In Uc: Clinical Resultsmentioning

confidence: 99%